CELU

Celularity is a pre-approval cellular-therapy company whose own 10-K states plainly that it has 'minimal cash on hand,' does not generate enough cash to operate the next twelve months, and that 'substantial doubt exists related to our ability to continue as a going concern.' That is not a soft caveat — it is the central fact. Cash and equivalents stood at just $6.17M against a $13.3M annual operating cash burn and $80.8M of current liabilities versus only $12.3M of current assets. The company survives only by raising 'substantial additional financing' through equity or debt, and it explicitly warns that failure to do so means it cannot continue. For a common shareholder, that is a setup for either dilution or wipeout.

The fundamentals confirm a deteriorating, unprofitable business rather than an early-stage story trending the right way. FY2025 revenue fell 51% to $26.6M (after a $54.2M FY2024 that itself did not stick), the net loss was $91.7M, operating margin was -230.9%, and stockholders' equity is negative at -$38.1M with a liabilities/equity of -3.82x. The accumulated deficit is -$991M — nearly a billion dollars of cumulative losses against a $17.9M market cap. Net income has been negative in four of the last five years, and the one positive year (FY2022, +$14.2M) was not driven by durable operations. Shares outstanding rose 21% in a single year, so existing holders are already being diluted while the burn continues; the Q1 2026 headcount and salary cuts are a survival measure, not a growth pivot.